Corus製藥控股 CRBP 深 滬
已收盤 10-17 16:00:00 美东时间
19.32
+0.270
+1.42%
華盛通- 最 高19.80
- 今 開18.92
- 成交量 46.43万股
- 最 低 18.01
- 昨 收 19.05
- 總市值 2.37亿
- 52周最高 20.77
- 市盈率 靜 --
- 換手率 3.79%
- 52周最低 4.64
- 委 比 -80.51%
- 總股本 1225.52万
- 歷史最高 323.40
- 量 比 1.24
- 振 幅 9.40%
- 歷史最低 3.00
- 每 手 1
- 風險率 3.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Corbus Pharmaceuticals Releases Abstract For Its Phase 1/2 Oncology Study Ahead Of Presentation At ESMO Congress 2025. Abstract Includes Safety Data From 70 Participants
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical stage company focused on oncology and obesity, announced today the European Society for Medical Oncology (ESMO) Congress 2025 abstract for its Phase 1/2
10-14 20:07
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025
Corbus Pharmaceuticals announced the release of an abstract for their Phase 1/2 clinical study of CRB-701, a next-generation antibody-drug conjugate targeting Nectin-4, to be presented at the European Society for Medical Oncology (ESMO) Congress 2025. The study involves 167 enrolled participants, with 122 evaluable for efficacy across various tumor types, including head and neck squamous cell carcinoma (HNSCC), cervical, and metastatic urothelial...
10-14 12:00
稳定币崛起 比特币的“货币支付梦”还能实现吗？
随着《GENIUS法案》巩固了由美国国债支持的稳定币地位，比特币凭借其去中心化特性成为推动数字美元革命的优越选择，应对多极化世界中美元需求下降的趋势。文章讨论了世界秩序从单极向多极的转变，美元面临的压力，以及比特币作为区块链网络的优势。稳定币在全球范围内的普及，尤其是在发展中国家，显示了美元需求的潜在增长。比特币的去中心化、隐私性和安全性使其成为未来全球经济的重要基础设施。 总结：《GENIUS法案》巩固了美元稳定币地位，比特币因其去中心化特性成为全球区块链的首选，应对多极化世界中美元需求下降的趋势。文章指出比特币独特的安全性与隐私性使其适合推动数字美元革命，确保美元在全球经济中的地位。
10-06 03:24
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025
Corbus Pharmaceuticals will host an in-person and virtual KOL event at ESMO 2025 to discuss Phase 1/2 dose optimization data for CRB-701, targeting cancers with high Nectin-4 expression. The event, featuring HNSCC experts Ari Rosenberg, Glenn Hanna, and Cesar Augusto Perez Batista, will offer insights from over 100 participants with head and neck, cervical, or metastatic urothelial tumors. A live Q&A will follow the presentation.
09-22 12:00
美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma
Corbus Pharmaceuticals Holdings, Inc. announced the U.S. FDA granted Fast Track designation for CRB-701 to treat recurrent or metastatic head and neck squamous cell carcinoma following platinum-based chemotherapy and anti-PD(L)-1 therapy. CRB-701, a next-generation antibody drug conjugate targeting Nectin-4, has already received Fast Track designation for relapsed or refractory metastatic cervical cancer in December 2024. The company will present...
09-16 12:00
谈一谈USDH竞标事件：会改变后续稳定币市场的游戏规则？
USDH竞标事件揭示稳定币市场变革：发行商竞相让利，显示流动性碎片化问题，传统发行方利润模式受挑战。Mert提出的解决方案在现实中难自洽，Hyperliquid通过转让铸币权，促使新发行方倒逼老发行方改变规则。事件标志着老旧稳定币发行方躺赢时代的结束，收益权逐步回归价值创造的应用方，对稳定币市场具有里程碑意义。
09-15 19:15
What Most Traders Miss When The Market Starts To Crack
On Wednesday, I showed you why we've officially entered one of the most dangero...
08-22 03:38
Corbus Pharmaceuticals Q2 EPS $(1.44) Beats $(1.52) Estimate
Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.44) per share which beat the analyst consensus estimate of $(1.52) by 5.39 percent. This is a 60 percent decrease over losses of $(0.90) per share
08-05 20:36
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals provided updates on its three clinical programs (CRB-701, CRB-913, and CRB-601), with data expected in the second half of 2025. CRB-701, targeting Nectin-4, will present Phase 1/2 dose expansion data at ESMO 2025. CRB-913, an obesity drug, initiated its MAD study and shows no neuropsychiatric events. CRB-601 is progressing in Phase 1. The company reported a Q2 2025 net loss of $17.7M, up due to increased R&D expenses, with ...
08-05 12:00
